Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma

Casale T. B.; Chipps B. E.; Rosen K.; Trzaskoma B.; Haselkorn T.; Omachi T. A.; Greenberg S.; Hanania N. A.

首页> 外文期刊>Allergy >Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma

【24h】

Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma

机译：使用患者富集标准从哮喘新的生物制剂试验中使用患者浓缩标准的回应

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Recent efficacy studies of asthma biologics have included highly enriched patient populations. Using a similar approach, we examined factors that predict response to omalizumab to facilitate selection of patients most likely to derive the greatest clinical benefit from therapy.

机译：背景：最近对哮喘生物学的疗效研究包括高度富集的患者群体。使用类似的方法，我们检查了预测对omalizumab的反应，以便于选择最有可能从治疗中获得最大的临床益处的患者的选择。

著录项

来源
《Allergy》 |2018年第2期|共8页
作者
Casale T. B.; Chipps B. E.; Rosen K.; Trzaskoma B.; Haselkorn T.; Omachi T. A.; Greenberg S.; Hanania N. A.;
展开▼
作者单位

Univ S Florida Div Allergy &

Immunol Tampa FL 33620 USA;

Capital Allergy &

Resp Dis Ctr Sacramento CA USA;

Genentech Inc San Francisco CA USA;

Genentech Inc San Francisco CA USA;

EpiMetrix Inc Los Altos CA USA;

Genentech Inc San Francisco CA USA;

Novartis Pharmaceut E Hanover NJ USA;

Baylor Coll Med Asthma Clin Res Ctr Sect Pulm &

Crit Care Med Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词
asthma; biologic therapy; biomarkers; eosinophils; omalizumab;

机译：哮喘;生物疗法;生物标志物;嗜酸性粒细胞;奥马尔齐齐;

相似文献

外文文献
中文文献
专利

1. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma [J] . Casale T. B., Chipps B. E., Rosen K., Allergy . 2018,第2期

机译：使用患者富集标准从哮喘新的生物制剂试验中使用患者浓缩标准的回应
2. DIFFERENCES IN ELIGIBILITY CRITERIA AND BASELINE PATIENT CHARACTERISTICS AMONGST TRIALS OF BIOLOGIC THERAPIES IN ASTHMA [J] . Bacharier L., Casale T., Holden M., Annals of allergy, asthma, and immunology . 2018,第5Suppla1期

机译：哮喘生物疗法试验中的资格标准和基线患者特征的差异
3. DIFFERENCES IN ELIGIBILITY CRITERIA AND BASELINE PATIENT CHARACTERISTICS AMONGST TRIALS OF BIOLOGIC THERAPIES IN ASTHMA [J] . L. Bacharier, T. Casale, M. Holden, Annals of allergy, asthma, and immunology . 2018,第5期

机译：哮喘生物疗法试验中的资格标准和基线患者特征的差异
4. Automatic Segregation and Classification of Inclusion and Exclusion Criteria of Clinical Trials to Improve Patient Eligibility Matching [C] . Tirthankar Dasgupta, Ishani Mondal, Abir Naskar, Health Intelligence Workshop;Association for the Advancement of Artificial Intelligence Annual Conference . 2020

机译：临床试验的自动分离与分类，改善患者资格匹配的临床试验
5. The effect of omalizumab on free IgE and spirometric measurements in allergic asthmatics with highly elevated IgE levels. [D] . Bonilla, Sheila M. 2011

机译：奥马珠单抗对IgE水平升高的过敏性哮喘患者中游离IgE和肺活量测定的影响。
6. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma [O] . T. B. Casale, B. E. Chipps, K. Rosén, -1

机译：使用来自哮喘新生物制剂的患者富集标准对奥马珠单抗的反应
7. Blood Eosinophils and Serum IgE Predict Response to Omalizumab in Patients with Severe Allergic Asthma: Innovate Trial Post-Hoc Analysis [O] . Volkan Manga, Marc Humbert, Ratko Djukanovic, 2016

机译：血嗜酸性粒细胞和血清IgE预测奥拉姆利亚症患者对严重过敏性哮喘的患者：创新试验后HOC分析

Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma

摘要

著录项

相似文献

相关主题

期刊订阅